0001209191-20-045489.txt : 20200806
0001209191-20-045489.hdr.sgml : 20200806
20200806164510
ACCESSION NUMBER: 0001209191-20-045489
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200605
FILED AS OF DATE: 20200806
DATE AS OF CHANGE: 20200806
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pedder Simon
CENTRAL INDEX KEY: 0001316736
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 201082378
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-05
0
0001300699
Athenex, Inc.
ATNX
0001316736
Pedder Simon
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO
NY
14203
0
1
0
0
See Remarks
Common Stock
5310
D
Stock Option (Right to Buy)
4.55
2017-05-13
2023-05-13
Common Stock
20000
20000
D
Stock Option (Right to Buy)
9.00
2020-02-28
2026-02-28
Common Stock
100000
100000
D
Stock Option (Right to Buy)
11.00
2027-06-13
Common Stock
130000
130000
D
Stock Option (Right to Buy)
17.30
2028-03-27
Common Stock
60000
60000
D
Stock Option (Right to Buy)
13.17
2029-02-28
Common Stock
60000
60000
D
Stock Option (Right to Buy)
12.45
2020-06-05
4
A
0
60000
0.00
A
2030-06-05
Common Stock
60000
60000
D
This option vests in four equal annual installments beginning on June 13, 2018.
This option vests in four equal annual installments beginning on March 27, 2019.
This option vests in four equal annual installments beginning on February 28, 2020.
These options were granted contingent on receiving shareholder approval of the Amended and Restated 2017 Omnibus Incentive Plan, which approval was received on June 5, 2020.
This option vests in four equal annual installments beginning on June 5, 2021.
/s/Teresa Bair, Attorney-in-Fact
2020-08-06